Please login (Members) to view content or
(Nonmembers) this article.

No votes yet

CNE Article

Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice

Virginia Bayer
Beau Amaya
Diane Baniewicz
Colleen Callahan
Lisa Marsh
Asia S. McCoy
CJON 2017, 21(2), 13-21 DOI: 10.1188/17.CJON.S2.13-21

Background: Significant research progress has been made in immunotherapies since the mid-1990s, and this rapid evolution necessitates evidence-based education on immunotherapies, their pathophysiology, and their toxicities to provide safe, effective care.

Objectives: The aim of this article is to provide an evidence-based overview, with implications for practice, of checkpoint inhibitors, monoclonal antibodies, oncolytic viral therapies, and chimeric antigen receptor T-cell therapies.

Methods: Each immunotherapy category is presented according to the pathophysiology of its immune modulation, the classes of agents within each category, evidence-based toxicities associated with each class, and implications for practice.

Findings: Immunotherapies vary in their pathophysiology and offer potential to be highly effective for the management of a wide array of cancer types. Understanding the unique pathophysiology and toxicities is necessary to assess, manage, and provide safe, effective patient-focused care.

Earn contact hours: ONS members can receive free CNE for reading this article and completing an evaluation online. To do so, click HERE or visit to access a current list of all available activities. This article's CNE is available for two years from the date of publication.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or